This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Vir Biotechnology (VIR) Down on Influenza Study Failure
by Zacks Equity Research
Vir Biotechnology (VIR) crashes after the phase II study evaluating VIR-2482 for preventing symptomatic influenza A illness fails to meet goals.
Alkermes (ALKS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Higher sales of Alkermes' (ALKS) key drugs like Vivitrol, Aristada and Lybalvi are likely to have driven second-quarter sales.
J&J (JNJ) Q2 Earnings & Sales Top, '23 View Upped, Stock Jumps
by Zacks Equity Research
J&J (JNJ) beats estimates for second-quarter earnings and sales. It raises full-year sales and earnings guidance.
Will Alnylam Pharmaceuticals (ALNY) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Recursion (RXRX) Stock Surges 191% in 3 Months: Here's Why
by Zacks Equity Research
Recursion's (RXRX) shares rallied almost 191% over the past three months, owing to artificial intelligence-driven acquisitions and strategic collaborations to advance drug development.
Apellis (APLS) Plunges on Safety Issues With Eye Treatment
by Zacks Equity Research
Apellis (APLS) suffers a setback on reports of six events of retinal vasculitis (or inflammation) following treatment with Syfovre (pegcetacoplan injection).
Alkermes (ALKS) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pieris (PIRS) Pursues Strategic Alternatives, Stock Rises
by Zacks Equity Research
Pieris (PIRS) announces strategic update after partner AstraZeneca terminated collaboration agreement and returned the rights to elarekibep.
Novartis (NVS) Q2 Earnings & Revenues Top, Guidance Raised
by Zacks Equity Research
Novartis (NVS) beats on earnings and sales in the second quarter and raises its annual guidance on strong momentum.
BridgeBio (BBIO) Up as Heart Drug Meets Primary Goal in Study
by Zacks Equity Research
BridgeBio's (BBIO) shares surge on announcing positive data from a late-stage study evaluating acoramidis for patients with transthyretin amyloid cardiomyopathy.
Corcept's (CORT) Early-Stage Study on NASH Reveals Positive Data
by Zacks Equity Research
Corcept's (CORT) early-stage candidate miricorilant, evaluated to treat patients with presumed non-alcoholic steatohepatitis, shows encouraging data.
Frequency (FREQ) Up 77% on Merger Deal With Korro Bio
by Zacks Equity Research
Post-merger, Frequency (FREQ) focuses on advancing RNA editing programs. This combined entity is set to operate under the name Korro Bio, which will apply to trade on the NASDAQ under the ticker symbol KRRO.
Gilead's (GILD) Veklury Gets FDA Nod for Label Expansion
by Zacks Equity Research
Gilead's (GILD) antiviral treatment Veklury (remdesivir) has now been approved for the treatment of COVID-19 patients with severe renal impairment, including those on dialysis.
Eli Lilly (LLY) to Buy Versanis, Strengthen Obesity Portfolio
by Zacks Equity Research
For the purchase of Versanis, Lilly (LLY) agrees to pay up to $1.93 billion in cash.
Perrigo (PRGO) Gets FDA Nod for First OTC Birth Control Pill
by Zacks Equity Research
Following the FDA approval, Perrigo's (PRGO) Opill is the first ever over-the-counter birth control pill. The drug will be made available in the United States early next year.
First Wave (FWBI) Down 32% on Cystic Fibrosis Study Setback
by Zacks Equity Research
Initial data from First Wave's (FWBI) mid-stage study evaluating its investigational oral capsule in cystic fibrosis patients did not likely meet its primary endpoint.
Liminal (LMNL) Up 40% on Buyout Offer From Majority Shareholder
by Zacks Equity Research
If the minority shareholders of Liminal BioSciences (LMNL) accept the buyout offer, they will receive $8.50 per share. This offer is a dollar more than the initial proposal received by management in April.
Are Medical Stocks Lagging Alkermes (ALKS) This Year?
by Zacks Equity Research
Here is how Alkermes (ALKS) and Haemonetics (HAE) have performed compared to their sector so far this year.
Here's Why Investors Should Add Encompass Health (EHC) to Portfolio
by Zacks Equity Research
Encompass Health (EHC) remains well-poised for growth on the back of solid demand for effective inpatient rehabilitation services, joint ventures and solid cash reserves.
Implied Volatility Surging for Alkermes (ALKS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Alkermes (ALKS) stock based on the movements in the options market lately.
Here's Why Alkermes (ALKS) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
Alkermes (ALKS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Factors That Make Universal Health (UHS) an Attractive Bet Now
by Zacks Equity Research
Universal Health (UHS) remains well-poised for growth on the resumption of elective surgeries, a diversified treatment network and solid cash reserves.
Caribou Biosciences (CRBU) Soars on $25M Investment by Pfizer
by Zacks Equity Research
Caribou Biosciences (CRBU) gets a major boost with a $25 million equity investment by Pfizer, which will accelerate the development of its allogeneic CAR-T cell therapy pipeline.
Here's Why You Should Add Alkermes (ALKS) to Your Portfolio
by Zacks Equity Research
Alkermes (ALKS), a top-ranked stock, has a diverse portfolio of neurological therapies. Its proprietary products are witnessing incremental sales.
Is Alkermes (ALKS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Alkermes (ALKS) and Masimo (MASI) have performed compared to their sector so far this year.